PharmaMar S.A. Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention

MADRID, April 21 /PRNewswire/ -- PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

Back to news